Monitor Toxicity, Anti-Cancer Drug Efficacy and Cytokine Response with New...
Monitor Toxicity, Anti-Cancer Drug Efficacy and Cytokine Response with New Bioluminescent Cytotoxicity Technology CytoTox-Glo™ Assay Launches at Screening Europe
MADISON, WISCONSIN (February 19, 2008)
Promega Corporation, a global leader in bioluminescent technologies and cell-based assays, announces the launch of the CytoTox-Glo™ Cytotoxicity Assay at the 5th annual Screening Europe conference and exhibition. Whether monitoring chemical toxicity, anti-cancer drug efficacy or cytokine response, the CytoTox-Glo Assay provides a highly sensitive, simple, luminescent method that allows the user to detect small changes in cell viability.
The assay measures a distinct "dead-cell" protease biomarker released from cells that have lost membrane integrity, a key indicator of cytotoxicity. The assay uses a peptide substrate, that after cleavage by the "dead-cell" protease, releases luciferin. This is a substrate for a proprietary thermostable luciferase (Ultra-Glo™ Recombinant Luciferase). The luciferase/luciferin reaction produces light in the form of a stable "glow-type" luminescent signal. The intensity of the signal correlates with dead-cell number.
The CytoTox-Glo Assay has a large dynamic range with excellent linearity, providing unprecedented sensitivity in 96-well plates or high-density formats. The high sensitivity and scalability minimizes both the number of cells required and the amount of compound used. This results in reduced cell culture and compound costs. Features of this assay are detailed in a talk by Promega:
Terry Riss, PhD, Senior R&D Scientist
"Multiplexing ADME-Tox Cell-based Assays Using Primary Cells"
Screening Europe on February 19, 2008 at 14:00 hours
Data Available Upon Request
About Promega
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit
www.promega.com.
These pages contain communications on Promega product releases and corporate activities. For additional new product information, see the new products page or the specific product or application area.
For more information about a new release article or about Promega in general, contact Penny Patterson at 1-608-274-4330 or complete this form.